Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 17.96% is 35% below its 5-year average of 27.82%, around the middle of its 5-year range (-49.00%–77.97%).
26.09% below its 12-month average of 24.30%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 34.61%.
EBITDA MARGIN
17.96%
EBITDA MARGIN AVG TTM
24.30%
EBITDA MARGIN AVG 3Y
30.39%
EBITDA MARGIN AVG 5Y
27.82%
EBITDA MARGIN AVG 10Y
35.88%
EBITDA MARGIN AVG 15Y
39.81%
EBITDA MARGIN AVG 20Y
39.34%
CURRENT VS TTM AVG
-26.09%
CURRENT VS 3Y AVG
-40.90%
CURRENT VS 5Y AVG
-35.45%
CURRENT VS 10Y AVG
-49.95%
CURRENT VS 15Y AVG
-54.89%
CURRENT VS 20Y AVG
-54.35%
Jazz Pharmaceuticals plc
Market Cap
$14.54B
EBITDA Margin
17.96%
TTM Avg
24.30%
3Y Avg
30.39%
5Y Avg
27.82%
Market Cap
$14.63B
EBITDA Margin
22.70%
TTM Avg
24.04%
3Y Avg
20.07%
5Y Avg
17.78%
Market Cap
$14.69B
EBITDA Margin
22.69%
TTM Avg
18.62%
3Y Avg
20.95%
5Y Avg
21.80%
Market Cap
$14.04B
EBITDA Margin
-16.47%
TTM Avg
-44.13%
3Y Avg
-328.90%
5Y Avg
-1924.25%
Market Cap
$15.07B
EBITDA Margin
32.07%
TTM Avg
25.68%
3Y Avg
26.69%
5Y Avg
27.49%
Market Cap
$13.81B
EBITDA Margin
-10046.24%
TTM Avg
-7368.03%
3Y Avg
-7368.04%
5Y Avg
-4939.80%
Market Cap
$13.11B
EBITDA Margin
-111.55%
TTM Avg
-188.02%
3Y Avg
-1871.48%
5Y Avg
-2339.83%
Market Cap
$13.01B
EBITDA Margin
64.75%
TTM Avg
63.53%
3Y Avg
56.52%
5Y Avg
57.35%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc (JAZZ) | $14.54B | 17.96% | 24.30% | 30.39% | 27.82% |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 22.70% | 24.04% | 20.07% | 17.78% |
| Exelixis, Inc. (EXEL)vs › | $14.66B | 38.84% | 34.03% | 26.26% | 22.70% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | 22.69% | 18.62% | 20.95% | 21.80% |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | -16.47% | -44.13% | -328.90% | -1924.25% |
| Solventum Corporation (SOLV)vs › | $15.07B | 32.07% | 25.68% | 26.69% | 27.49% |
| Summit Therapeutics Inc. (SMMT)vs › | $13.81B | -10046.24% | -7368.03% | -7368.04% | -4939.80% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | -111.55% | -188.02% | -1871.48% | -2339.83% |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 64.75% | 63.53% | 56.52% | 57.35% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 6.13% | 13.31% | 19.35% | 24.86% |
Gross Margin
84.7%
EBITDA Margin
18.0%
Operating Margin
5.3%
Net Margin
20.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 34.61% |
| 2026-03-31 | 36.97% |
| 2025-12-31 | 77.97% |
| 2025-09-30 | 20.94% |
| 2025-06-30 | -49.00% |
| 2025-03-31 | 12.14% |
| 2024-12-31 | 33.01% |
| 2024-09-30 | 40.33% |
| 2024-06-30 | 35.40% |
| 2024-03-31 | 25.45% |
| 2023-12-31 | 27.84% |
| 2023-09-30 | 34.45% |
| 2023-06-30 | 33.14% |
| 2023-03-31 | 31.74% |
| 2022-12-31 | -12.21% |
| 2022-09-30 | 18.45% |
| 2022-06-30 | 25.91% |
| 2022-03-31 | 32.84% |
| 2021-12-31 | 23.86% |
| 2021-09-30 | 23.38% |
| 2021-06-30 | 10.34% |
| 2021-03-31 | 38.69% |
| 2020-12-31 | 36.83% |
| 2020-09-30 | 44.55% |
| 2020-06-30 | 47.27% |
| 2020-03-31 | -22.87% |
| 2019-12-31 | 41.12% |
| 2019-09-30 | 37.19% |
| 2019-06-30 | 50.40% |
| 2019-03-31 | 38.21% |
| 2018-12-31 | 49.42% |
| 2018-09-30 | 51.06% |
| 2018-06-30 | 42.34% |
| 2018-03-31 | 32.51% |
| 2017-12-31 | 45.35% |
| 2017-09-30 | 33.22% |
| 2017-06-30 | 49.27% |
| 2017-03-31 | 43.86% |
| 2016-12-31 | 49.24% |
| 2016-09-30 | 44.32% |
| 2016-06-30 | 51.94% |
| 2016-03-31 | 43.55% |
| 2015-12-31 | 39.04% |
| 2015-09-30 | 47.00% |
| 2015-06-30 | 53.73% |
| 2015-03-31 | 46.45% |
| 2014-12-31 | 49.96% |
| 2014-09-30 | 29.53% |
| 2014-06-30 | 37.41% |
| 2014-03-31 | -13.84% |
| 2013-12-31 | 49.20% |
| 2013-09-30 | 52.13% |
| 2013-06-30 | 46.61% |
| 2013-03-31 | 45.01% |
| 2012-12-31 | 48.89% |
| 2012-09-30 | 44.11% |
| 2012-06-30 | 42.77% |
| 2012-03-31 | 45.60% |
| 2011-12-31 | 47.45% |
| 2011-09-30 | 48.63% |
| 2011-06-30 | 55.46% |
| 2011-03-31 | 48.29% |
| 2010-12-31 | 51.66% |
| 2010-09-30 | 36.85% |
| 2010-06-30 | 31.74% |
| 2010-03-31 | 27.26% |
| 2009-12-31 | 36.03% |
| 2009-09-30 | 19.90% |
| 2009-06-30 | 27.43% |
| 2009-03-31 | -23.20% |
| 2008-12-31 | -244.49% |
| 2008-09-30 | -133.25% |
| 2008-06-30 | -274.29% |
| 2008-03-31 | -281.28% |
| 2007-12-31 | -362.32% |
| 2007-09-30 | -70.68% |
| 2007-06-30 | -281.40% |
| 2007-03-31 | -119.67% |
| 2006-12-31 | -952.93% |
| 2006-09-30 | 100.00% |
| 2006-06-30 | 100.00% |
| 2006-03-31 | 100.00% |
| 2005-12-31 | -1366.16% |
| 2005-09-30 | 100.00% |
| 2005-06-30 | 100.00% |
| 2005-03-31 | 100.00% |
